Complement factor I in health and disease

Molecular Immunology

Volumn 48, Issue 14, 2011, Pages 1611-1620

  Nilsson, Sara C ^a   Sim, Robert B ^b   Lea, Susan M ^c   Fremeaux Bacchi, Veronique ^d   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Complement system; Factor I

Indexed keywords

COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX; LOW DENSITY LIPOPROTEIN; SERINE PROTEINASE;

ACUTE KIDNEY FAILURE; COMPLEMENT DEFICIENCY; DISULFIDE BOND; HUMAN; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

COMPLEMENT FACTOR I; DIMERIZATION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MODELS, IMMUNOLOGICAL; MUTATION; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 79960446438     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.04.004     Document Type: Review

References (95)

1. Abramson N., Alper C.A., Lachmann P.J., Rosen F.S., Jandl J.H. Deficiency of C3 inactivator in man. J. Immunol. 1971, 107:19-27.
2. Adams E.M., Brown M.C., Nunge M., Krych M., Atkinson J.P. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J. Immunol. 1991, 147:3005-3011.
3. Amadei N., Baracho G.V., Nudelman V., Bastos W., Florido M.P., Isaac L. Inherited complete factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H. Scand. J. Immunol. 2001, 53:615-621.
4. Baracho G.V., Nudelman V., Isaac L. Molecular characterization of homozygous hereditary factor I deficiency. Clin. Exp. Immunol. 2003, 131:280-286.
5. Bienaime F., Dragon-Durey M.A., Regnier C.H., Nilsson S.C., Kwan W.H., Blouin J., Jablonski M., Renault N., Rameix-Welti M.A., Loirat C., Sautes-Fridman C., Villoutreix B.O., Blom A.M., Fremeaux-Bacchi V. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010, 77:339-349.
6. Blom A.M., Kask L., Dahlback B. Structural requirements for the complement regulatory activities of C4BP. J. Biol. Chem. 2001, 276:27136-27144.
7. Blom A.M., Kask L., Dahlback B. CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Mol. Immunol. 2003, 39:547-556.
8. Blom A.M., Mark L., Spiller O.B. Viral heparin-binding complement inhibitors-a recurring theme. Adv. Exp. Med. Biol. 2007, 598:105-125.
9. Bossi F., Bulla R., Tedesco F. Endothelial cells are a target of both complement and kinin system. Int. Immunopharmacol. 2008, 8:143-147.
10. Boyer O., Noel L.H., Balzamo E., Guest G., Biebuyck N., Charbit M., Salomon R., Fremeaux-Bacchi V., Niaudet P. Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. Am. J. Kidney Dis. 2008, 51:671-677.
11. Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., Mele C., Bresin E., Cassis L., Gamba S., Porrati F., Bucchioni S., Monteferrante G., Fang C.J., Liszewski M.K., Kavanagh D., Atkinson J.P., Remuzzi G. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
12. Catterall C.F., Lyons A., Sim R.B., Day A.J., Harris T.J. Characterization of primary amino acid sequence of human complement control protein factor I from an analysis of cDNA clones. Biochem. J. 1987, 242:849-856.
13. Chamberlain D., Ullman C.G., Perkins S.J. Possible arrangement of the five domains in human complement factor I as determined by a combination of X-ray and neutron scattering and homology modeling. Biochemistry 1998, 37:13918-13929.
14. Chan M.R., Thomas C.P., Torrealba J.R., Djamali A., Fernandez L.A., Nishimura C.J., Smith R.J., Samaniego M.D. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am. J. Kidney Dis. 2009, 53:321-326.
15. Crossley L.G. C3b inactivator and beta 1H. Methods Enzymol. 1981, 80:112-124.
16. Cruzado J.M., de Cordoba S.R., Melilli E., Bestard O., Rama I., Sanchez-Corral P., Lopez-Trascasa M., Navarro I., Torras J., Goma M., Grinyo J.M. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am. J. Transplant. 2009, 9:1477-1483.
17. DiScipio R.G. Ultrastructures and interactions of complement factors H and I. J. Immunol. 1992, 149:2592-2599.
18. Dragon-Durey M.A., Blanc C., Marliot F., Loirat C., Blouin J., Sautes-Fridman C., Fridman W.H., Fremeaux-Bacchi V. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 2009, 46:447-450.
19. Ekdahl K.N., Nilsson U.R., Nilsson B. Inhibition of factor I by diisopropylfluorophosphate. Evidence of conformational changes in factor I induced by C3b and additional studies on the specificity of factor I. J. Immunol. 1990, 144:4269-4274.
20. Esparza-Gordillo J., Jorge E.G., Garrido C.A., Carreras L., Lopez-Trascasa M., Sanchez-Corral P., de Cordoba S.R. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol. Immunol. 2006, 43:1769-1775.
21. Fakhouri F., Fremeaux-Bacchi V., Noel L.H., Cook H.T., Pickering M.C. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 2010, 6:494-499.
22. Fakhouri F., Roumenina L., Provot F., Sallee M., Caillard S., Couzi L., Essig M., Ribes D., Dragon-Durey M.A., Bridoux F., Rondeau E., Fremeaux-Bacchi V. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 2010, 21:859-867.
23. Fearon D.T. Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J. Immunol. 1977, 119:1248-1252.
24. Fevig J.M., Buriak J., Cacciola J., Alexander R.S., Kettner C.A., Knabb R.M., Pruitt J.R., Weber P.C., Wexler R.R. Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile. Bioorg. Med. Chem. Lett. 1998, 8:301-306.
25. Foreman K.E., Vaporciyan A.A., Bonish B.K., Jones M.L., Johnson K.J., Glovsky M.M., Eddy S.M., Ward P.A. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 1994, 94:1147-1155.
26. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., Loirat C., Rondeau E., Fridman W.H. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 2004, 41:e84.
27. Gasque P., Julen N., Ischenko A.M., Picot C., Mauger C., Chauzy C., Ripoche J., Fontaine M. Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol. 1992, 149:1381-1387.
28. Geelen J., van den Dries K., Roos A., van de Kar N., de Kat Angelino C., Klasen I., Monnens L., van den Heuvel L. A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr. Nephrol. 2007, 22:371-375.
29. Genel F., Sjoholm A.G., Skattum L., Truedsson L. Complement factor I deficiency associated with recurrent infections, vasculitis and immune complex glomerulonephritis. Scand. J. Infect. Dis. 2005, 37:615-618.
30. Goldberg R.J., Nakagawa T., Johnson R.J., Thurman J.M. The role of endothelial cell injury in thrombotic microangiopathy. Am. J. Kidney Dis. 2010, 56:1168-1174.
31. Goldberger G., Arnaout M.A., Aden D., Kay R., Rits M., Colten H.R. Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J. Biol. Chem. 1984, 259:6492-6497.
32. Goldberger G., Bruns G.A., Rits M., Edge M.D., Kwiatkowski D.J. Human complement factor I: analysis of cDNA-derived primary structure and assignment of its gene to chromosome 4. J. Biol. Chem. 1987, 262:10065-10071.
33. Igarashi Y., Eroshkin A., Gramatikova S., Gramatikoff K., Zhang Y., Smith J.W., Osterman A.L., Godzik A. CutDB: a proteolytic event database. Nucleic Acids Res. 2007, 35:D546-D549.
34. Isenman D.E. Conformational changes accompanying proteolytic cleavage of human complement protein C3b by the regulatory enzyme factor I and its cofactor H. Spectroscopic and enzymological studies. J. Biol. Chem. 1983, 258:4238-4244.
35. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444:213-216.
36. Julen N., Dauchel H., Lemercier C., Sim R.B., Fontaine M., Ripoche J. In vitro biosynthesis of complement factor I by human endothelial cells. Eur. J. Immunol. 1992, 22:213-217.
37. Kajander T., Lehtinen M.J., Hyvarinen S., Bhattacharjee A., Leung E., Isenman D.E., Meri S., Goldman A., Jokiranta T.S. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2897-2902.
38. Kavanagh D., Kemp E.J., Mayland E., Winney R.J., Duffield J.S., Warwick G., Richards A., Ward R., Goodship J.A., Goodship T.H. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2005, 16:2150-2155.
39. Kavanagh D., Richards A., Noris M., Hauhart R., Liszewski M.K., Karpman D., Goodship J.A., Fremeaux-Bacchi V., Remuzzi G., Goodship T.H., Atkinson J.P. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol. Immunol. 2008, 45:95-105.
40. Krych M., Hauhart R., Atkinson J.P. Structure-function analysis of the active sites of complement receptor type 1. J. Biol. Chem. 1998, 273:8623-8629.
41. Lachmann P.J., Muller-Eberhard H.J. The demonstration in human serum of " conglutinogen-activating factor" and its effect on the third component of complement. J. Immunol. 1968, 100:691-698.
42. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 2008, 6:132-142.
43. Laursen N.S., Andersen K.R., Braren I., Spillner E., Sottrup-Jensen L., Andersen G.R. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J. 2011, 30:606-616.
44. Le Quintrec M., Roumenina L., Noris M., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin. Thromb. Hemost. 2010, 36:641-652.
45. Leroy V., Fremeaux-Bacchi V., Peuchmaur M., Baudouin V., Deschenes G., Macher M.A., Loirat C. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatr. Nephrol. 2011, 26:419-424.
46. Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum. Mutat. 2010, 31:E1445-E1460.
47. Malhotra R., Priest R., McDowell W., Telaranta A., Hood C. Expression and characterization of the serine protease domain of human complement components. Inflamm. Res. 2003, 52:S165.
48. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 2007, 171:715-727.
49. Minta J.O., Fung M., Paramaswara B. Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by interleukin-6. Biochim. Biophys. Acta 1998, 1442:286-295.
50. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., Schmidt C.Q., Staniforth S.J., Holmes L.V., Ward R., Morgan L., Goodship T.H., Marchbank K.J. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
51. Morgan H.P., Schmidt C.Q., Guariento M., Blaum B.S., Gillespie D., Herbert A.P., Kavanagh D., Mertens H.D., Svergun D.I., Johansson C.M., Uhrin D., Barlow P.N., Hannan J.P. Structural basis for engagement by complement factor H of C3b on a self surface. Nat. Struct. Mol. Biol. 2011, 18:463-470.
52. Morris K.M., Aden D.P., Knowles B.B., Colten H.R. Complement biosynthesis by the human hepatoma-derived cell line HepG2. J. Clin. Invest. 1982, 70:906-913.
53. Nilsson S.C., Kalchishkova N., Trouw L.A., Fremeaux-Bacchi V., Villoutreix B.O., Blom A.M. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur. J. Immunol. 2010, 40:172-185.
54. Nilsson S.C., Karpman D., Vaziri-Sani F., Kristoffersson A.C., Salomon R., Provot F., Fremeaux-Bacchi V., Trouw L.A., Blom A.M. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol. Immunol. 2007, 44:1845-1854.
55. Nilsson S.C., Trouw L.A., Renault N., Miteva M.A., Genel F., Zelazko M., Marquart H., Muller K., Sjoholm A.G., Truedsson L., Villoutreix B.O., Blom A.M. Genetic, molecular and functional analyses of complement factor I deficiency. Eur. J. Immunol. 2009, 39:310-323.
56. Nita I.M., Genel F., Nilsson S.C., Smart J., Truedsson L., Choo S., Blom A.M. Molecular characterization of two novel cases of complete complement inhibitor factor I deficiency. Mol. Immunol. 2011, 48:1068-1072.
57. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E.M., Zipfel P.F., Goodship T.H., Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 2010, 5:1844-1859.
58. Okroj M., Hsu Y.F., Ajona D., Pio R., Blom A.M. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol. Immunol. 2008, 45:169-179.
59. Pangburn M.K., Muller-Eberhard H.J. Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factors H and I. Biochemistry 1983, 22:178-185.
60. Paramaswara B., Minta J.O. An initiator element and a proximal cis-acting sequence are essential for transcriptional activation of the complement factor I (CFI) gene. Gene 1999, 237:71-80.
61. Pettigrew H.D., Teuber S.S., Gershwin M.E. Clinical significance of complement deficiencies. Ann. N.Y. Acad. Sci. 2009, 1173:108-123.
62. Polley M.J., Nachman R.L. Human platelet activation by C3a and C3a des-arg. J. Exp. Med. 1983, 158:603-615.
63. Rawlings N.D., Barrett A.J., Bateman A. MEROPS: the peptidase database. Nucleic Acids Res. 2010, 38:D227-D233.
64. Ricklin D., Tzekou A., Garcia B.L., Hammel M., McWhorter W.J., Sfyroera G., Wu Y.Q., Holers V.M., Herbert A.P., Barlow P.N., Geisbrecht B.V., Lambris J.D. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J. Immunol. 2009, 183:2565-2574.
65. Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., Ricklin D., Lambris J.D., Janssen B.J., van Strijp J.A., Gros P. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 2009, 10:721-727.
66. Rupin A., Mennecier P., Lila C., de Nanteuil G., Verbeuren T.J. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Thromb. Haemost. 1997, 78:1221-1227.
67. Saadi S., Holzknecht R.A., Patte C.P., Stern D.M., Platt J.L. Complement-mediated regulation of tissue factor activity in endothelium. J. Exp. Med. 1995, 182:1807-1814.
68. Sadallah S., Gudat F., Laissue J.A., Spath P.J., Schifferli J.A. Glomerulonephritis in a patient with complement factor I deficiency. Am. J. Kidney Dis. 1999, 33:1153-1157.
69. Scheer M., Grote A., Chang A., Schomburg I., Munaretto C., Rother M., Sohngen C., Stelzer M., Thiele J., Schomburg D. BRENDA, the enzyme information system in 2011. Nucleic Acids Res. 2011, 39:D670-D676.
70. Sellier-Leclerc A.L., Fremeaux-Bacchi V., Dragon-Durey M.A., Macher M.A., Niaudet P., Guest G., Boudailliez B., Bouissou F., Deschenes G., Gie S., Tsimaratos M., Fischbach M., Morin D., Nivet H., Alberti C., Loirat C. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2007, 18:2392-2400.
71. Servais A., Fremeaux-Bacchi V., Lequintrec M., Salomon R., Blouin J., Knebelmann B., Grunfeld J.P., Lesavre P., Noel L.H., Fakhouri F. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J. Med. Genet. 2007, 44:193-199.
72. Seya T., Nagasawa S. Limited proteolysis of complement protein C3b by regulatory enzyme C3b inactivator: isolation and characterization of a biologically active fragment C3d,g. J. Biochem. 1985, 97:373-382.
73. Seya T., Nakamura K., Masaki T., Ichihara-Itoh C., Matsumoto M., Nagasawa S. Human factor H and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b. Mol. Immunol. 1995, 32:355-360.
74. Shiang R., Murray J.C., Morton C.C., Buetow K.H., Wasmuth J.J., Olney A.H., Sanger W.G., Goldberger G. Mapping of the human complement factor I gene to 4q25. Genomics 1989, 4:82-86.
75. Sim E., Wood A.B., Hsiung L.M., Sim R.B. Pattern of degradation of human complement fragment C3b. FEBS Lett. 1981, 132:55-60.
76. Sim R.B., Day A.J., Moffatt B.E., Fontaine M. Complement factor I and cofactors in control of complement system convertase enzymes. Methods Enzymol. 1993, 223:13-35.
77. Sjoberg A.P., Trouw L.A., Blom A.M. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009, 30:83-90.
78. Soames C.J., Sim R.B. Interactions between human complement components factor H, factor I and C3b. Biochem. J. 1997, 326(Pt 2):553-561.
79. Tedesco F., Pausa M., Nardon E., Introna M., Mantovani A., Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 1997, 185:1619-1627.
80. Thai C.T., Ogata R.T. Complement components C5 and C7: recombinant factor I modules of C7 bind to the C345C domain of C5. J. Immunol. 2004, 173:4547-4552.
81. Timar K.K., Junnikkala S., Dallos A., Jarva H., Bhuiyan Z.A., Meri S., Bos J.D., Asghar S.S. Human keratinocytes produce the complement inhibitor factor I: synthesis is regulated by interferon-gamma. Mol. Immunol. 2007, 44:2943-2949.
82. Tsiftsoglou S.A., Sim R.B. Human complement factor I does not require cofactors for cleavage of synthetic substrates. J. Immunol. 2004, 173:367-375.
83. Tsiftsoglou S.A., Willis A.C., Li P., Chen X., Mitchell D.A., Rao Z., Sim R.B. The catalytically active serine protease domain of human complement factor I. Biochemistry 2005, 44:6239-6249.
84. Ullman C.G., Chamberlain D., Ansari A., Emery V.C., Haris P.I., Sim R.B., Perkins S.J. Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Mol. Immunol. 1998, 35:503-512.
85. Ullman C.G., Perkins S.J. The factor I and follistatin domain families: the return of a prodigal son. Biochem. J. 1997, 326:939-941.
86. Vyse T.J., Bates G.P., Walport M.J., Morley B.J. The organization of the human complement factor I gene (IF): a member of the serine protease gene family. Genomics 1994, 24:90-98.
87. Vyse T.J., Morley B.J., Bartok I., Theodoridis E.L., Davies K.A., Webster A.D., Walport M.J. The molecular basis of hereditary complement factor I deficiency. J. Clin. Invest. 1996, 97:925-933.
88. Welch T.R., Blystone L.W. Renal disease associated with inherited disorders of the complement system. Pediatr. Nephrol. 2009, 24:1439-1444.
89. Westra D., Volokhina E., van der Heijden E., Vos A., Huigen M., Jansen J., van Kaauwen E., van der Velden T., van de Kar N., van den Heuvel L. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol. Dial. Transplant. 2010, 25:2195-2202.
90. Whaley K. Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J. Exp. Med. 1980, 151:501-516.
91. Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., Fairbrother W.J., McCallum S.A., Embuscado L., DeForge L., Hass P.E., van Lookeren Campagne M. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006, 444:217-220.
92. Wong M.J., Goldberger G., Isenman D.E., Minta J.O. Processing of human factor I in COS-1 cells co-transfected with factor I and paired basic amino acid cleaving enzyme (PACE) cDNA. Mol. Immunol. 1995, 32:379-387.
93. Wong P.C., Pinto D.J., Knabb R.M. Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc. Drug. Rev. 2002, 20:137-152.
94. Wu J., Wu Y.Q., Ricklin D., Janssen B.J., Lambris J.D., Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 2009, 10:728-733.
95. Zuber J., Le Quintrec M., Sberro-Soussan R., Loirat C., Fremeaux-Bacchi V., Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat. Rev. Nephrol. 2011, 7:23-35.